Celularity Inc. (CELU)
CELU Stock Price Chart
Explore Celularity Inc. interactive price chart. Choose custom timeframes to analyze CELU price movements and trends.
CELU Company Profile
Discover essential business fundamentals and corporate details for Celularity Inc. (CELU) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Aug 2019
Employees
120.00
Website
https://www.celularity.comCEO
Robert Joseph Hariri
Description
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
CELU Financial Timeline
Browse a chronological timeline of Celularity Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
Earnings released on 30 Apr 2026
EPS came in at -$0.95 surpassing the estimated -$1.50 by +36.67%, while revenue for the quarter reached $4.10m , meeting expectations.
Earnings released on 14 Nov 2025
EPS came in at -$0.88 surpassing the estimated -$1.50 by +41.33%, while revenue for the quarter reached $5.28m .
Earnings released on 29 Aug 2025
EPS came in at -$0.84 , while revenue for the quarter reached $11.43m .
Earnings released on 8 May 2025
EPS came in at -$0.59 surpassing the estimated -$1.50 by +60.67%, while revenue for the quarter reached $18.13m , beating expectations by +248.69%.
Earnings released on 6 Dec 2024
EPS came in at -$0.73 surpassing the estimated -$1.40 by +47.86%, while revenue for the quarter reached $9.30m , beating expectations by +75.40%.
Earnings released on 7 Nov 2024
EPS came in at -$0.30 surpassing the estimated -$1.40 by +78.57%, while revenue for the quarter reached $12.11m , beating expectations by +175.25%.
Earnings released on 27 Sept 2024
EPS came in at $3.40 , while revenue for the quarter reached $14.68m .
Earnings released on 31 Jul 2024
EPS came in at $0.54 , while revenue for the quarter reached $12.11m , beating expectations by +157.26%.
Stock split effective on 29 Feb 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 2 Jan 2024
EPS came in at -$0.60 falling short of the estimated -$0.04 by -1.57k%, while revenue for the quarter reached $3.79m , missing expectations by -86.09%.
Earnings released on 14 Aug 2023
EPS came in at $3.40 surpassing the estimated -$0.30 by +1.23k%, while revenue for the quarter reached $2.94m , missing expectations by -89.21%.
Earnings released on 22 May 2023
EPS came in at -$2.20 surpassing the estimated -$2.40 by +8.33%, while revenue for the quarter reached $3.94m , missing expectations by -30.23%.
Earnings released on 31 Mar 2023
EPS came in at -$0.03 surpassing the estimated -$0.25 by +88.00%, while revenue for the quarter reached $4.13m , missing expectations by -24.65%.
Earnings released on 10 Nov 2022
EPS came in at $0.30 surpassing the estimated -$2.60 by +111.54%, while revenue for the quarter reached $4.14m , missing expectations by -27.98%.
Earnings released on 9 Aug 2022
EPS came in at $0.30 surpassing the estimated -$2.60 by +111.54%, while revenue for the quarter reached $3.78m , missing expectations by -30.56%.
Earnings released on 16 May 2022
EPS came in at -$4.80 falling short of the estimated -$2.30 by -108.70%, while revenue for the quarter reached $5.94m , beating expectations by +16.60%.
Earnings released on 31 Mar 2022
EPS came in at -$0.30 surpassing the estimated -$2.90 by +89.66%, while revenue for the quarter reached $4.86m , beating expectations by +5.97%.
Earnings released on 12 Nov 2021
EPS came in at $4.00 surpassing the estimated -$2.90 by +237.93%, while revenue for the quarter reached $10.62m , missing expectations by -65.02%.
Earnings released on 16 Aug 2021
EPS came in at -$2.69 falling short of the estimated -$0.16 by -1.58k%, while revenue for the quarter reached $3.20m .
CELU Stock Performance
Access detailed CELU performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
